Shares of Acadia Healthcare Co. (NASDAQ:ACHC) saw unusually-strong trading volume on Monday . Approximately 1,515,050 shares were traded during trading, an increase of 27% from the previous session’s volume of 1,196,627 shares.The stock last traded at $54.10 and had previously closed at $56.50.

A number of equities research analysts recently weighed in on ACHC shares. Zacks Investment Research raised Acadia Healthcare from a “hold” rating to a “buy” rating and set a $66.00 price objective on the stock in a research report on Tuesday, April 19th. Mizuho raised their price objective on Acadia Healthcare from $66.00 to $71.00 and gave the company a “buy” rating in a research report on Friday, April 29th. Robert W. Baird reiterated a “buy” rating on shares of Acadia Healthcare in a research note on Monday, May 16th. Leerink Swann reiterated an “outperform” rating and issued a $90.00 price target on shares of Acadia Healthcare in a research note on Friday, July 15th. Finally, Jefferies Group reiterated a “buy” rating and issued a $85.00 price target on shares of Acadia Healthcare in a research note on Monday, June 27th. One research analyst has rated the stock with a sell rating, one has given a hold rating and twelve have assigned a buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $79.14.

The company has a market capitalization of $4.60 billion and a P/E ratio of 31.27. The firm’s 50-day moving average is $55.47 and its 200 day moving average is $56.97.

Acadia Healthcare (NASDAQ:ACHC) last released its earnings results on Friday, July 29th. The company reported $0.73 EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.73. During the same period in the previous year, the firm earned $0.57 earnings per share. The company had revenue of $756.50 million for the quarter, compared to analyst estimates of $752.57 million. The company’s revenue for the quarter was up 66.8% compared to the same quarter last year. On average, equities analysts predict that Acadia Healthcare Co. will post $2.77 EPS for the current year.

A number of hedge funds and institutional investors recently added to or reduced their stakes in the company. US Bancorp DE boosted its position in Acadia Healthcare by 29.1% in the fourth quarter. US Bancorp DE now owns 23,508 shares of the company’s stock valued at $1,469,000 after buying an additional 5,298 shares during the last quarter. Trexquant Investment LP boosted its position in Acadia Healthcare by 93.3% in the fourth quarter. Trexquant Investment LP now owns 27,300 shares of the company’s stock valued at $1,705,000 after buying an additional 13,176 shares during the last quarter. Rhumbline Advisers boosted its position in Acadia Healthcare by 6.1% in the fourth quarter. Rhumbline Advisers now owns 53,198 shares of the company’s stock valued at $3,323,000 after buying an additional 3,045 shares during the last quarter. Mutual of America Capital Management LLC boosted its position in Acadia Healthcare by 0.3% in the fourth quarter. Mutual of America Capital Management LLC now owns 57,344 shares of the company’s stock valued at $3,582,000 after buying an additional 194 shares during the last quarter. Finally, California Public Employees Retirement System boosted its position in Acadia Healthcare by 0.9% in the fourth quarter. California Public Employees Retirement System now owns 82,700 shares of the company’s stock valued at $5,165,000 after buying an additional 700 shares during the last quarter.

Acadia Healthcare Company, Inc is a provider of behavioral healthcare services. The Company operates in two segments: U.S. Facilities and U.K. Facilities. The Company develops and operates inpatient psychiatric facilities, residential treatment centers, group homes, substance abuse facilities and facilities providing outpatient behavioral healthcare services to serve the behavioral health and recovery needs of communities throughout the United States, the United Kingdom and Puerto Rico.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.